Opus Genetics (fka Ocuphire Pharma) Files 8-K
Ticker: IRD · Form: 8-K · Filed: Jan 23, 2025 · CIK: 1228627
Sentiment: neutral
Topics: corporate-action, name-change
TL;DR
Opus Genetics, formerly Ocuphire Pharma, filed an 8-K confirming its name changes.
AI Summary
On January 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing indicates that the company's former name was Ocuphire Pharma, Inc., with a name change occurring on November 9, 2020. Prior to that, it was Rexahn Pharmaceuticals, Inc., and before that, Corporate Road Show Dot Com Inc. The company is incorporated in Delaware and its principal executive offices are located in Durham, NC.
Why It Matters
This filing clarifies the corporate lineage and former names of Opus Genetics, Inc., which can be important for investors tracking the company's history and potential liabilities or successes under previous identities.
Risk Assessment
Risk Level: low — This filing is primarily administrative, confirming historical company name changes and basic corporate information, posing no immediate new risks.
Key Numbers
- 001-34079 — SEC File Number (Identifies the company's filing with the SEC.)
- 11-3516358 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Opus Genetics, Inc. (company) — Registrant
- Ocuphire Pharma, Inc. (company) — Former name
- Rexahn Pharmaceuticals, Inc. (company) — Previous former name
- Corporate Road Show Dot Com Inc (company) — Earliest former name
- January 23, 2025 (date) — Date of report
- November 9, 2020 (date) — Date of name change from Ocuphire Pharma, Inc.
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report current information about Opus Genetics, Inc., specifically confirming its corporate identity and historical name changes.
When did Opus Genetics, Inc. officially change its name from Ocuphire Pharma, Inc.?
The name change from Ocuphire Pharma, Inc. to Opus Genetics, Inc. occurred on November 9, 2020.
What were the previous names of Opus Genetics, Inc. before Ocuphire Pharma, Inc.?
Before being known as Ocuphire Pharma, Inc., the company was formerly Rexahn Pharmaceuticals, Inc., and prior to that, Corporate Road Show Dot Com Inc.
In which state is Opus Genetics, Inc. incorporated?
Opus Genetics, Inc. is incorporated in Delaware.
What is the principal executive office address for Opus Genetics, Inc.?
The principal executive offices of Opus Genetics, Inc. are located at 8 Davis Drive, Suite 220, Durham, NC 27709.
Filing Stats: 839 words · 3 min read · ~3 pages · Grade level 14.9 · Accepted 2025-01-23 17:20:36
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share IRD The Nasdaq
Filing Documents
- ef20041877_8k.htm (8-K) — 29KB
- 0001140361-25-001819.txt ( ) — 163KB
- ird-20250123.xsd (EX-101.SCH) — 4KB
- ird-20250123_lab.xml (EX-101.LAB) — 21KB
- ird-20250123_pre.xml (EX-101.PRE) — 16KB
- ef20041877_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events The 2025 Annual Meeting of Stockholders (the "2025 Annual Meeting") of Opus Genetics, Inc. (the "Company") has been scheduled for April 30, 2025. Due to the fact that the date for the 2025 Annual Meeting is more than 30 days prior to the anniversary of the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the Company is providing the new deadline for submission of any qualified stockholder proposal or qualified stockholder nomination. Stockholders who wish to bring a director nomination or stockholder proposal before the 2025 Annual Meeting other than by means of inclusion of a stockholder proposal in the Company's proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must comply with the requirements set forth in the Company's Amended and Restated Bylaws (the "Bylaws"). The advance notice provisions of the Bylaws contain informational content requirements that must be met when providing notice to the Company of matters to be brought before the 2025 Annual Meeting. Because the 2025 Annual Meeting will occur more than 30 days prior to the anniversary of the 2024 Annual Meeting, the Bylaws require that any such stockholder's notice with respect to the 2025 Annual Meeting be delivered to, or mailed and received by the Secretary of the Company at the principal executive office of the Company by the later of 90 days prior to the date of the 2025 Annual Meeting and 10 days following the day on which public announcement of the date of the 2025 Annual Meeting is first made. For the 2025 Annual Meeting, such deadline falls on February 2, 2025. To comply with the universal proxy rules pursuant to Rule 14a-19 under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must additionally provide notice to the Company setting forth the information required by Rule 14a-19(b) under the Exchange Act